BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study

This publication has 38 references indexed in Scilit:

• Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases
  Lung Cancer, 2015
• Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
  Proceedings of the National Academy of Sciences, 2013
• Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
  Cancer Science, 2012
• Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
  JAMA, 2012
• The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
  Nature Genetics, 2011
• Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin
  Clinical Cancer Research, 2011
• Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB
  Nature, 2010
• Malignant mesothelioma
  The Lancet, 2005
• Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
  Journal of Clinical Oncology, 2003
• Loss of p16 expression is associated with histological features of melanoma invasion
  Melanoma Research, 2002